       Document 0965
 DOCN  M9620965
 TI    Factors associated with the development of Pneumocystis carinii
       pneumonia in 5,025 European patients with AIDS. AIDS in Europe Study
       Group.
 DT    9602
 AU    Lundgren JD; Barton SE; Lazzarin A; Danner S; Goebel FD; Pehrson P;
       Mulcahy F; Kosmidis J; Pedersen C; Phillips AN; Hvidovre Hospital,
       Denmark.
 SO    Clin Infect Dis. 1995 Jul;21(1):106-13. Unique Identifier : AIDSLINE
       MED/96065622
 AB    This study examined the factors associated with the development of a
       first episode of Pneumocystis carinii pneumonia (PCP) in 5,025 patients
       with AIDS, including 1,976 patients with primary PCP at the time of AIDS
       diagnosis and 635 with primary PCP occurring subsequently. Compared with
       untreated patients, patients treated with zidovudine were at similar
       risk of developing PCP during the first year of therapy but were at
       greater risk after longer intervals of treatment. The following factors
       were associated with an increased risk of PCP (either at the time of
       AIDS diagnosis or thereafter): lack of primary PCP prophylaxis, male
       homosexuality/bisexuality, diagnosis of AIDS in northern Europe, and CD4
       cell count below 200 x 10(6)/L at the time of AIDS diagnosis. Patients
       with severe weight loss had a 60% higher risk of developing PCP during
       follow-up than those without such weight loss. Thus, the occurrence of
       PCP depended on geographic location, mode of acquisition of human
       immunodeficiency virus and AIDS, degree of immunodeficiency, and use of
       various treatment regimens.
 DE    Adult  Antiviral Agents/THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/DIAGNOSIS/DRUG THERAPY/  *EPIDEMIOLOGY  Bisexuality  Cohort
       Studies  CD4 Lymphocyte Count  Europe/EPIDEMIOLOGY  Female
       Homosexuality, Male  Human  Incidence  Male  Middle Age  Pneumonia,
       Pneumocystis carinii/DIAGNOSIS/DRUG THERAPY/  *EPIDEMIOLOGY  Risk
       Factors  Substance Abuse, Intravenous/COMPLICATIONS  Support, Non-U.S.
       Gov't  Weight Loss  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE
       MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

